Date: 2014-07-17
Type of information: Loan
Company: BioAlliance Pharma (France)
Investors: Financière de la Montagne (France)
Amount: €10 million
Funding type: loan
Planned used: This loan helps strengthen the financial resources of BioAlliance Pharma, and those of Onxeo following completion of the company’s merger with Topotarget. In particular, the loan supports its R&D programs, including the international phase III clinical trial with Livatag® in primary liver cancer.
Others: * On July 18, 2014, BioAlliance Pharma announced the setup of a €10 million loan granted by its top shareholder, Financière de la Montagne. A BioAlliance Pharma shareholder since 2008, today its top shareholder and member of its Board of Directors, Financière de la Montagne thus confirms its commitment to the Company. The loan is granted for a one-year period, until July 31st 2015, in the form of a shareholders’ current account and will bear a 15% interest payable at maturity. Capital and interest are repayable in cash, or in shares in case the company launches a capital increase prior to the end of the loan agreement. The debt incorporated for the subscription to the capital increase would then be increased by a 25% premium.
Therapeutic area: Cancer - Oncology - Rare diseases
